Imagine you're a translator working between two people who speak different dialects of the same language. One person hands you their medical chart — full of implicit dates, unstated follow-up windows, and columns that mean different things depending on which hospital generated them. The other person hands you a study protocol that assumes clean, labeled variables with precise temporal boundaries. Your job isn't creative writing; it's contract negotiation. You must produce a binding agreement about what the data can actually say, then compile the study request against that contract. That's ProCARE. The committed claim: LLM agents can automate real-world studies (RWS) on electronic health records reliably only if you first convert the dataset's messy clinical semantics into a formal "Evidence Contract" and then compile the study objective into a strongly typed intermediate representation (RWS-IR) — not if you let the agent free-associate SQL. The authors argue that every prior LLM-agent approach to clinical data analysis is brittle precisely because it skips this grounding step, leading to schema mismatches, temporal errors, wrong analytical units, and unsupported clinical conclusions. The architecture is a two-stage compiler pipeline. Stage one: heterogeneous data profiles (variable inventories, temporal attributes, distributions, evidentiary limits) are converted into Evidence Contracts — formal specifications of what the data can and cannot support. Stage two: study objectives are compiled into RWS-IR, a typed intermediate representation that binds variables, time relations, analysis units, and statistical tasks. Deterministic validators then check and locally repair the generated workflow across five phases: schema mapping, cohort construction, variable derivation, analysis, and interpretation. This is not end-to-end neural — it's neural generation sandwiched between hard constraint layers. On the ladder: ProCARE is evaluated on 36 EHR-based benchmark tasks against "strong LLM-agent baselines" (the paper's phrase). It outperforms on three axes — code executability, semantic consistency, and conclusion traceability. The automated violation detection shows moderate-to-substantial agreement with blinded expert review. That said, the baselines are other LLM agents, not established epidemiological software pipelines or human analyst teams running the same 36 tasks independently. The paper is honest about the comparison class it chose, but the strongest classical baseline — a trained biostatistician with SAS — is not in the ring. Integrity is mixed-to-solid. The benchmark is custom-built (36 tasks), not a pre-existing community standard, which introduces selection risk. However, the blinded expert review is a genuine integrity move: having domain experts independently assess violation diagnoses without knowing which system produced them is harder to game than automated metrics alone. Code and benchmark are released on GitHub, which is the right move. No pre-registration, and no independent replication yet — both expected for a first publication. The milestone question is about coverage and trust. 36 EHR tasks is a proof of concept. The real unlock is whether this framework can handle the diversity of real-world observational datasets — claims data, registries, multi-site EHRs with different schemas — at scale. The next concrete number to watch: can ProCARE handle 200+ tasks across 5+ heterogeneous data sources with maintained semantic consistency? That's the threshold where a pharma company or FDA reviewer would consider trusting it for regulatory-grade evidence generation. The obvious experiment not run: head-to-head comparison against experienced human biostatisticians on the same 36 tasks, measuring time-to-completion and error rates. The honest read is (a) — this would be expensive, slow, and logistically brutal to organize with blinded conditions. It's the study that would make the paper's practical claim credible to clinical operations teams, and it's almost certainly planned for a follow-up or industry collaboration.
